9,10-seco- Cyclopentanohydrophenanthrene Ring System (e.g., Vitamin D, Etc.) Doai Patents (Class 514/167)
-
Patent number: 9901576Abstract: Stable phenobarbital sodium solutions for injection that do not generate impurities during extended storage. These solutions include phenobarbital sodium in an amount of 15 to 200 mg/mL; a C1-C4 alcohol such as ethanol in an amount of 105 to 160 mg/mL; and a glycol such as propylene glycol in an amount of between 620 and 830 mg/mL and have a pH of between 9 and 12 which is adjusted to that range by adding acid or base, as required. No more than 50 mg/mL water is present including any water introduced by the acid or base. The solutions contain no more than 0.8% of phenyl ethyl acetyl urea impurity as well as no detectable amount of phenyl butyric acid after two years storage at room temperature.Type: GrantFiled: November 18, 2016Date of Patent: February 27, 2018Assignee: West-Ward Pharmaceuticals International LimitedInventors: Michael G. Parker, Scott S. Wilson, Yasmeen Chahal, Kelly W. Hovius, David E. McAnany
-
Patent number: 9877975Abstract: The present invention aims to provide an agent for treating meibomian gland dysfunction. The present invention provides an agent for treating meibomian gland dysfunction, which contains activated vitamin D3 or a derivative thereof as an active ingredient.Type: GrantFiled: June 27, 2014Date of Patent: January 30, 2018Assignee: Keio UniversityInventors: Kazuo Tsubota, Reiko Arita, Masataka Ito
-
Patent number: 9861644Abstract: A stabilized formulation for controlled release of a vitamin D compound is disclosed. The formulation comprises one or both of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 and a cellulosic compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.Type: GrantFiled: March 14, 2014Date of Patent: January 9, 2018Assignee: OPKO IRELAND GLOBAL HOLDINGS, LTD.Inventors: Jay A. White, Samir P. Tabash, Sammy A. Agudoawu, Joel Z. Melnick
-
Patent number: 9844565Abstract: The present invention generally relates to compositions and methods for treatment of subjects having or at risk of acne or other conditions. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto a location with acne, or on another suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.Type: GrantFiled: September 30, 2016Date of Patent: December 19, 2017Assignee: Transdermal Biotechnology, Inc.Inventor: Nicholas V. Perricone
-
Patent number: 9814736Abstract: Disclosed are methods of administering 2-methylene-19-nor-(20S)-1?,25-dihydroxyvitamin D3 to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism, including a subject previously administered a calcimimetic.Type: GrantFiled: October 31, 2016Date of Patent: November 14, 2017Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Lori A. Plum, Margaret Clagett-Dame
-
Patent number: 9775903Abstract: This present disclosure is directed to novel prodrugs of activated vitamin D3 compounds. The prodrugs can be designed to have one or more beneficial properties, such as selective inhibition of the enzyme CYP24, low calcemic activity, and anti-proliferative activity. Specifically, these prodrugs are 1-deoxy prohormones of active Vitamin D analogs, e.g. analogs of calcitriol. This disclosure is also directed to pharmaceutical and diagnostic compositions containing the prodrugs of the invention, and to their medical use, particularly as prodrugs in the treatment and/or prevention of diseases.Type: GrantFiled: January 13, 2011Date of Patent: October 3, 2017Assignees: JOHNS HOPKINS UNIVERSITY, OPKO IRELAND GLOBAL HOLDINGS, LTD.Inventors: Gary H. Posner, Lindsey C. Hess, Alvin S. Kalinda, Rachel D. Slack, Uttam Saha, P. Martin Petkovich
-
Patent number: 9757392Abstract: The present invention discloses a novel use of a lanostane having the following formula (I) in enhancing uptake of nutrients: wherein R1 is either H or CH3; R2 is OCOCH3, ?O or OH; R3 is H or OH; R4 is —C(?CH2)—C(CH3)2Ra, in which Ra is H or OH, or —CH?C(CH3)—Rb, in which Rb is CH3 or CH2OH; R5 is H or OH; and R6 is CH3 or CH2OH.Type: GrantFiled: March 31, 2009Date of Patent: September 12, 2017Assignee: Sinphar Pharmaceutical Co., Ltd.Inventors: Hang-Ching Lin, Tsu-Chung Chang, Wen-Liang Chang, Yi-Yang Song
-
Patent number: 9717704Abstract: The present invention relates to the treatment and/or prevention of Alzheimer's Disease or the symptoms associated therewith by daily administration of a drink formula comprising fresh marine omega-3 oil in an emulsion and resveratrol or derivatives thereof.Type: GrantFiled: June 13, 2014Date of Patent: August 1, 2017Assignee: Smartfish ASInventors: Janne Sande Mathisen, Henrik Mathisen
-
Patent number: 9722880Abstract: The preferred embodiments of the present invention are directed to a network tracing engine for tracing and depicting a topology (i.e. a network configuration) of a network using, for example, a network diagram. The network tracing engine preferably queries/telnets to interfaces of routers associated with one or more source-to-destination paths in a network concurrently and independently to ensure proper configuration of the routers and/or to generate a true depiction of a routing configuration without redundantly querying routers.Type: GrantFiled: April 12, 2016Date of Patent: August 1, 2017Assignee: AT&T INTELLECTUAL PROPERTY I, L.P.Inventor: Raymond Washburn
-
Patent number: 9707243Abstract: The topical composition with Vitamin D3 includes Vitamin D3, one or more aromatic oils, and aloe vera gel. Vitamin D3 is soluble in aromatic oils, and aloe vera gel enables transport through the stratum corneum so that the composition may be used for fulfilling daily requirements, treatment of bone conditions, such as rickets and osteomalacia, and supportive therapy in osteopenia and osteoporosis. The aromatic oil may be a citric acid extract (e.g., orange oil extracted from orange peels), lavender oil, or any other aromatic oil in which Vitamin D3 is soluble. Optionally, the composition may include excipients, such as a permeability enhancer (e.g., glycerine and water), a preservative (e.g., a carbomer, methyl paraben, EDTA, or the like), or other additives that do not affect the active ingredients. The composition is preferably formulated as a cream or emulsion.Type: GrantFiled: March 10, 2014Date of Patent: July 18, 2017Inventors: Sadat A. Ali, Haifa Abdulaziz Alturki
-
Patent number: 9687441Abstract: Compositions for lubricating skin during application of a fascia tissue treatment device, thereby reducing the appearance of cellulite in skin and methods of forming such compositions.Type: GrantFiled: June 14, 2016Date of Patent: June 27, 2017Assignee: Ashley Diana Black International Holdings, LLCInventor: Ashley D. Black
-
Patent number: 9671414Abstract: Described herein are assays directed to determining the level of bioavailable or free vitamin D in a blood sample in a subject. The values determined for bioavailable or free vitamin D indicate whether the subject suffers from insufficient levels of vitamin D. Also described herein are methods of treatment for vitamin D insufficiency.Type: GrantFiled: May 2, 2014Date of Patent: June 6, 2017Assignees: Beth Israel Deaconess Medical Center, Inc., The General Hospital CorporationInventors: Ravi Thadhani, S. Ananth Karumanchi, Anders Hayden Berg, Ishir Bhan
-
Patent number: 9663429Abstract: The present invention relates to compounds of pharmaceutical interest. More particularly, it relates to compounds of formula (I), to processes for obtaining thereof, to the intermediates of their synthesis and processes for obtaining the latter. The compounds of formula (I) have a certain affinity with the vitamin D receptor, they are active in a similar order to 1,25?-dihydroxyvitamin D3 (1,25D), with the advantage of producing less or no hypercalcemia.Type: GrantFiled: November 19, 2014Date of Patent: May 30, 2017Assignees: UNIVERSIDADE DE SANTIAGO DE COMPOSTELA, UNIVERSIDADE DA CORUNA, SERVIZO GALEGO DE SAUDE (SERGAS)Inventors: Roman Perez Fernandez, Samuel Seoane Ruzo, Antonio Mouriño Mosquera, Miguel Maestro Saavedra, Jose Esteban Castelao Fernandez, Pranjal Gogoi
-
Patent number: 9606131Abstract: Described herein are assays directed to determining the level of bioavailable or free vitamin D in a blood sample in a subject. The values determined for bioavailable or free vitamin D indicate whether the subject suffers from insufficient levels of vitamin D. Also described herein are methods of treatment for vitamin D insufficiency.Type: GrantFiled: May 11, 2015Date of Patent: March 28, 2017Assignees: The General Hospital Corporation, Beth Israel Deaconess Medical Center, Inc.Inventors: Ravi Thadhani, S. Ananth Karumanchi, Anders Hayden Berg, Ishir Bhan
-
Patent number: 9539264Abstract: Disclosed are methods of administering 2-methylene-19-nor-(20S)-1?,25-dihydroxyvitamin D3 to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism, including a subject previously administered a calcimimetic.Type: GrantFiled: May 13, 2015Date of Patent: January 10, 2017Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Lori A. Plum, Margaret Clagett-Dame
-
Patent number: 9539231Abstract: A targeted approach toward the treatment of TN breast cancer by using AMPI-109 is disclosed. AMPI-109 is a compound with remarkable “cancer-specific” characteristics. In particular, AMPI-109 demonstrates a striking targeted capability to inhibit the proliferation of TN breast cancer cells and to induce apoptosis in TN breast cancer cells. The growth inhibitory effect of AMPI-109 is independent of VDR. AMPI-109 can also be coupled with other oncolytic agents in treating a patient with TN breast cancer.Type: GrantFiled: January 17, 2014Date of Patent: January 10, 2017Assignees: The Regents of the University of Colorado, a body corporate, Trustees of Boston UniversityInventors: Hamid Gari, Jim Lambert, Scott Lucia, Rahul Ray, Ann Thor
-
Patent number: 9517241Abstract: Methods of treating patients with inflammatory bowel disease, intestinal fibrosis, or Crohn's disease involve administering a therapeutic amount of CARD-024 or related compound.Type: GrantFiled: February 24, 2016Date of Patent: December 13, 2016Assignee: The Regents Of The University Of MichiganInventors: Robert U. Simpson, Peter D. R. Higgins, Laura A. Johnson
-
Patent number: 9492493Abstract: A softgel of NLKJ for the treatment of prostate diseases, comprising 0.05-1.0 g of NLKJ and 0.05-1.5 mg of an antioxidant, said NLKJ having the following physicochemical parameter: acid value<0.56, iodine value 95.0-107.00, saponification value 185.00-195.00, specific gravity 0.914-0.918 (20° C.), and refractive index 1.470-1.475 (20° C.). The inhibition of the softgel of NLKJ on the growth of prostate cancer in combination with the injection of Lupron is stronger than that of each of them used alone.Type: GrantFiled: September 21, 2012Date of Patent: November 15, 2016Inventor: Dapeng Li
-
Patent number: 9492552Abstract: The invention relates to injectable pharmaceutical compositions, methods of use and formulation, wherein the compositions comprise: one or more water soluble complexes, each complex comprising a cyclodextrin or a cyclodextrin derivative and a hydrophobic drug; at least one preservative; and at least one co-solvent. The compositions are effectively preserved in accordance with the European Pharmacopoeia 2011 Test for Efficacy of Antimicrobial Preservation, satisfying at least the B criteria as it applies to parenterals, and the United States Pharmacopeia 2011 Guidelines for Antimicrobial Effectiveness Testing, satisfying the criteria for Category 1 (injectable) products.Type: GrantFiled: November 27, 2012Date of Patent: November 15, 2016Assignee: JUROX PTY LTDInventors: Kirby Shawn Pasloske, Kai Lau, Sarah Jane Richardson, Amanda Aileen Willis
-
Patent number: 9465039Abstract: The application discloses PERLECAN as a new biomarker for renal dysfunction; methods for predicting, diagnosing, prognosticating and/or monitoring said dysfunction based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods.Type: GrantFiled: August 5, 2011Date of Patent: October 11, 2016Assignee: MYCARTIS NVInventors: Koen Kas, Griet Vanpoucke, Piet Moerman
-
Patent number: 9402855Abstract: The method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies.Type: GrantFiled: November 19, 2012Date of Patent: August 2, 2016Assignees: OPKO RENAL, LLC, OPKO IRELAND GLOBAL HOLDINGS, LTD.Inventors: Charles W. Bishop, Keith H. Crawford, Eric J. Messner, P. Martin Petkovich, Christian F. Helvig
-
Patent number: 9387201Abstract: This disclosure provides products, including pharmaceutical compositions and dietary supplements, which are useful for anti-inflammatory support.Type: GrantFiled: January 29, 2014Date of Patent: July 12, 2016Assignee: RCP Development, Inc.Inventor: Jonnie R. Williams
-
Patent number: 9381183Abstract: This invention relates to methods for improving changing the quality of the meibum composition of the meibomian glands to enhance or improve the lipid layer of the tear and increase tear breakup time by way of elevating the omega-3 index in patients suffering from symptoms of dry eye, posterior blepharitis, and/or meibomian gland dysfunction. The methods comprise administering a supplementation of omega-3 fatty acids to a patient having an inflamed meibomian gland so as to facilitate an increase in the amount of omega-3's acting as an anti-inflammatory and, respectively, decrease the amount of omega-6's (arachidonic acid) acting as an inflammatory in the composition of the meibum, thereby normalizing the lipid layer of the tear and effectively reducing the associated symptoms. In certain embodiments, the supplementation of omega-3's comprises the esterified or re-esterified triglyceride form.Type: GrantFiled: March 12, 2013Date of Patent: July 5, 2016Assignee: Physicians Recommended Nutriceuticals, LLCInventors: S. Gregory Smith, Michael B. Gross, Olav E. Sandnes
-
Patent number: 9370527Abstract: Methods of treating patients with inflammatory bowel disease, intestinal fibrosis, or Crohn's disease involve administering a therapeutic amount of CARD-024 or related compound.Type: GrantFiled: December 19, 2013Date of Patent: June 21, 2016Assignee: The Regents Of The University Of MichiganInventors: Robert U. Simpson, Peter D. R. Higgins, Laura A. Johnson
-
Patent number: 9359277Abstract: The present invention relates to compositions, for example, the DBU/Hexafluoroacetone hydrate salt, and processes of preparing and using the same for the modification of chemical compounds via the release of trifluoroacetate. The DBU/Hexafluoroacetone hydrate salt can perform trifluoromethylation reactions on chemical compounds, such as carbonyl group-containing compounds.Type: GrantFiled: March 22, 2012Date of Patent: June 7, 2016Assignee: Purdue Research FoundationInventors: David A. Colby, Mark V. Riofski, Changho Han
-
Patent number: 9320764Abstract: A method for enhancing production of Vitamin D within a person's skin includes a source of Vitamin D, a sunlight exposure indicator, and a sunscreen. Vitamin D, for example, cod liver oil, is applied to the skin topically via a patch or towlette, or ingested orally. The exposure indicator is worn by the user and changes its state to indicate that the person has been exposed to sunlight for a predetermined period of time. The user preferably waits a sufficient time for the Vitamin D to be absorbed into the skin, and then exposes his or her skin to direct sunlight, and monitors the exposure indicator to determine if it has changed state. The user applies the sunscreen to the user's skin after the exposure indicator changes state.Type: GrantFiled: February 1, 2011Date of Patent: April 26, 2016Assignee: TOPICAL TECHNOLOGIES, INC.Inventor: David S. Alberts
-
Patent number: 9241919Abstract: Embodiments of the invention relate to methods and compositions for treating symptoms related to inflammatory conditions and to methods and compositions for treating inflammatory components of common cold, utilizing various method of administration of X-ray contrast media (CM).Type: GrantFiled: April 18, 2013Date of Patent: January 26, 2016Assignee: 3E THERAPEUTICS CORPORATIONInventors: Elliott C. Lasser, Kenneth H. Lasser
-
Patent number: 9241904Abstract: The present invention is related to metered dose inhalation formulas and manufacturing process. The active pharmaceutical ingredient can be beta-2 agonists, corticosteroids, or a combination thereof. The inhalation formulas are homogenized suspensions with hydrofluoroalkane (HFA) propellant, minimal amount of ethanol and polyetheleneglycol (PEG) as suspending and particle size modifying agents.Type: GrantFiled: February 14, 2012Date of Patent: January 26, 2016Assignee: INTECH BIOPHARM LTD.Inventors: Wei-Hsiu Wu, Yen-Chin Chao
-
Patent number: 9212136Abstract: The present invention is directed to novel processes for the preparation of paricalcitol to novel intermediates used in these processes, and to processes for preparation of the novel intermediates.Type: GrantFiled: July 22, 2009Date of Patent: December 15, 2015Assignees: AZAD PHARMACEUTICALS INGREDIENTS AG, UNIVERSITAT ZURICHInventors: Thomas Bader, Alfred Stutz, Hans-Ulrich Bichsel, Changchun Fu
-
Patent number: 9212137Abstract: Disclosed are methods of purifying the compound (20R,22R)-2-methylene-19-nor-22-methyl-1?,25-dihydroxyvitamin D3 to obtain the compound in crystalline form. The methods typically include the steps of dissolving a product containing the compound in a solvent comprising hexane and 2-propanol, cooling the solvent and dissolved product below ambient temperature for a sufficient amount of time to form a precipitate of crystals, and recovering the crystals. Certain diol precursors formed during the synthesis of the compound and its diasteromers also may be obtained in crystalline form using ethyl acetate as a solvent.Type: GrantFiled: March 14, 2013Date of Patent: December 15, 2015Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Pawel Grzywacz, Lori A. Plum, Agnieszka Flores, James B. Thoden, Hazel M. Holden
-
Patent number: 9161941Abstract: The present invention is a compound comprising an NSAID portion and at least one of a progestin portion and a progesterone portion. The compound may take for instance the form of a pill or pellet (for oral internal use or for subdermal implantation), an injectable solution, or a suppository. The compound is intended for use in treating subjects having or being at increased risk—especially genetically determined risk—of developing endometriosis. The compound may also be used for treating other disorders or as a contraceptive.Type: GrantFiled: May 19, 2014Date of Patent: October 20, 2015Assignee: Predictive Therapeutics, LLCInventor: Bradley C. Robinson
-
Patent number: 9149499Abstract: The present invention is a compound comprising a cannabis portion and at least one of a progestin portion and a progesterone portion. The compound may optionally also include an NSAID component. The compound may take for instance the form of a pill or pellet (for oral internal use or for subdermal implantation), an injectable solution, or a suppository. The compound is intended for use in treating subjects having or being at increased risk—especially genetically determined risk—of developing endometriosis. The compound may also be used for treating other disorders or as a contraceptive.Type: GrantFiled: May 19, 2014Date of Patent: October 6, 2015Assignee: Predictive Therapeutics, LLCInventor: Bradley C. Robinson
-
Patent number: 9132219Abstract: A method of predicting serum potassium concentrations in a patient during hemodialysis includes measuring serum potassium concentrations of the patient over a hemodialysis treatment session time and an ultrafiltration rate calculated by a difference between pre- and post-dialytic body weight of the patient during an initial hemodialysis treatment session divided by a total treatment time of the treatment session and estimating a potassium mobilization clearance and a pre-dialysis distribution volume of potassium for the patient. Serum potassium concentrations of the patient can then be predicted at any time during any hemodialysis treatment session with the estimated potassium mobilization clearance and pre-dialysis distribution volume of potassium of the patient.Type: GrantFiled: August 16, 2013Date of Patent: September 15, 2015Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Alp Akonur, John Kenneth Leypoldt, Yin-Cheng Lo, Baris Ugar Agar
-
Patent number: 9066958Abstract: Composition of vitamin D in medium-chain triglycerides and use thereof in delivering a nutritional or therapeutic amount of vitamin D to a human being, particularly, an infant. The compositions are applied to an object, such as skin or in the case of an infant to a woman's nipple or pacifier from which the infant sucks off the composition. The method provides a more suitable, safer and efficient way of providing the human being with vitamin D. The compositions further comprise a free fatty acid and/or monoglyceride, oxidant preservative and, optionally, other vitamins.Type: GrantFiled: February 13, 2007Date of Patent: June 30, 2015Inventors: Reinhold W. Vieth, Elaine Vieth
-
Patent number: 9052308Abstract: Described herein are assays directed to determining the level of bioavailable or free vitamin D in a blood sample in a subject. The values determined for bioavailable or free vitamin D indicate whether the subject suffers from insufficient levels of vitamin D. Also described herein are methods of treatment for vitamin D insufficiency.Type: GrantFiled: June 14, 2013Date of Patent: June 9, 2015Assignees: The General Hospital Corporation, Beth Israel Deaconess Medical Center, Inc.Inventors: Ravi Thadhani, S. Ananth Karumanchi, Anders Hayden Berg, Ishir Bhan
-
Publication number: 20150141385Abstract: Methods for diagnosing, treating, and preventing catabolism-related vitamin D deficiency and related disorders, related compositions, apparatus and kits, are disclosed. A method involves measuring CYP24 expression and/or activity, or a proxy thereof such as FGF23 level, in a patient and correlating abnormally elevated CYP24 expression and/or activity with catabolism-related vitamin D deficiency or with susceptibility for catabolism-related vitamin D deficiency. In response to abnormally elevated CYP24 expression and/or activity, the method further includes administering a CYP24 inhibitor to the vitamin D deficient or at-risk patient, and preferably avoiding activation of the vitamin D binding receptor, such as by avoiding administration of active vitamin D compounds to such patients. Optionally, a vitamin D prohormone or prohormone can be administered.Type: ApplicationFiled: January 28, 2015Publication date: May 21, 2015Inventors: P. Martin Petkovich, Christian F. Helvig, Joel Z. Melnick
-
Patent number: 9034853Abstract: Disclosed are methods of administering 2-methylene-19-nor-(20S)-1?,25-dihydroxyvitamin D3 to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism.Type: GrantFiled: March 7, 2014Date of Patent: May 19, 2015Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Julia B. Zella, Lori A. Plum, Margaret Clagett-Dame
-
Publication number: 20150126464Abstract: A primary objective is to provide a drug for radical cure and a therapeutic method for diseases associated with axonal dysfunction (for example, Alzheimer's disease, dementia, Parkinson's disease, spinal cord injury, or brain contusion) based on the pathogenic mechanism thereof. Provided is a compound having a stimulating activity on 1,25D3-MARRS or a pharmaceutically acceptable salt thereof. Also provided is a technical idea relating to a pharmaceutical composition for disease treatment comprising a therapeutically effective amount thereof, a production method, a method for preventing or treating a disease, and a kit.Type: ApplicationFiled: July 24, 2013Publication date: May 7, 2015Inventor: Chihiro Tohda
-
Publication number: 20150118298Abstract: Described herein are pharmaceutical compositions comprising polyunsaturated fatty acids and methods of manufacturing the same. In particular, described herein are pharmaceutical compositions comprising soft enteric capsules comprising omega-3 polyunsaturated fatty acids. The oral pharmaceutical compositions described herein are useful as nutritional supplements or for the treatment of cardiovascular-related diseases, such as hyper dyslipidemia and high triglyceride levels.Type: ApplicationFiled: October 29, 2014Publication date: April 30, 2015Inventors: Peijin Zhang, Aqeel A. Fatmi
-
Publication number: 20150118186Abstract: New pyrazole derivatives having the chemical structure of formula (I) are disclosed; as well as process for theft preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).Type: ApplicationFiled: January 5, 2015Publication date: April 30, 2015Inventors: Jordi BACH TAÑA, Lluis Miquel PAGES SANTACANA, Joan TALTAVULL MOLL, Paul Robert EASTWOOD, Jacob GONZALEZ RODRIGUES, Victor GIULIO MATASSA
-
Patent number: 9018194Abstract: The present invention provides a compound which functions as a selective vitamin D receptor modulator and has action-selectivity or tissue-selectivity such that it does not induce hypercalcemia but causes other effects. There is provided a compound represented by formula (I), a solvate thereof or a prodrug thereof. wherein m and n each independently represent 1 or 0; R represents a hydrogen atom or an alkyl group; Y represents an ethane-1,1-diyl group or an ethyne-1,2-diyl group; and Z1 represents a hydrogen atom and Z2 represents a hydroxyalkoxy group, or Z1 and Z2 jointly form a methylene group.Type: GrantFiled: March 1, 2012Date of Patent: April 28, 2015Assignees: Nibon UniversityInventors: Makoto Makishima, Sachiko Yamada, Antonio Mourino, Hiroaki Tokiwa, Takeru Kudo, Yusuke Watarai, Kazuki Maekawa
-
Patent number: 9018175Abstract: The compounds of Formula (1), in which A, R1, R2, R3 and R5 have the meanings as given in the description, are novel effective inhibitors of type 4 and 5 phosphodiesterase.Type: GrantFiled: December 15, 2010Date of Patent: April 28, 2015Assignee: Takeda GmbHInventors: Dieter Flockerzi, Thomas Stengel, Alexander Mann, Harald Ohmer, Ulrich Kautz, Steffen Weinbrenner, Stefan Fischer, Christof Zitt, Armin Hatzelmann, Torsten Dunkern, Christian Hesslinger, Thomas Maier, Hermann Tenor, Clemens Braun, Raimund Külzer, Degenhard Marx
-
Patent number: 9006220Abstract: To provide a novel vitamin D3 derivative useful as a therapeutic agent for osteoporosis. Provided is a vitamin D3 derivative represented by the following formula (1) or a medicinally acceptable solvate thereof: wherein R1 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, an alkylcarbonyloxyalkyl group with each alkyl having 1 to 6 carbon atoms, or an arylcarbonyloxyalkyl group with the aryl having 6 to 10 carbon atoms and the alkyl having 1 to 6 carbon atoms; R2 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms or, together with the other R2 and the carbon atom to which they are bound to, may form a cyclic alkyl group having 3 to 6 carbon atoms; R3 represents an alkyl group having 1 to 6 carbon atoms or, together with the other R3 and the carbon atom to which they are bound to, may form a cyclic alkyl group having 3 to 6 carbon atoms; X represents an oxygen atom or a methylene group; and n represents an integer of 1 or 2.Type: GrantFiled: October 24, 2011Date of Patent: April 14, 2015Assignee: Teijin Pharma LimitedInventors: Hiroshi Saito, Masato Komiyama, Eiji Ochiai, Kenichiro Takagi, Takayuki Chida, Mariko Fujita, Keiichiro Imaizumi, Toshiyuki Kaneko
-
Patent number: 8993547Abstract: This invention discloses 3-desoxy-2-methylene-19-nor-vitamin D analogs, and specifically (20S)-3-desoxy-2-methylene-1?,25-dihydroxy-19-nor-vitamin D3 and (20R)-3-desoxy-2-methylene-1?,25-dihydroxy-19-nor-vitamin D3 as well as pharmaceutical uses therefor. These compounds exhibit relatively high binding activity and pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to monocytes thus evidencing use as anti-cancer agents especially for the treatment or prevention of osteosarcoma, leukemia, colon cancer, breast cancer, skin cancer or prostate cancer. These compounds also exhibit relatively high calcemic activity evidencing use in the treatment of bone diseases.Type: GrantFiled: June 13, 2012Date of Patent: March 31, 2015Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Lori A. Plum, Rafal R. Sicinski, Izabela Sibilska, Margaret Clagett-Dame
-
Patent number: 8987235Abstract: This invention discloses N-cyclopropyl-(20R)-2-methylene-19,26,27-trinor-25-aza-vitamin D analogs, and specifically N-cyclopropyl-(20R)-2-methylene-19,26,27-trinor-25-aza-1?-hydroxyvitamin D3 and pharmaceutical uses therefor. This compound exhibits relatively high binding activity and pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent especially for the treatment or prevention of leukemia, colon cancer, breast cancer, skin cancer or prostate cancer.Type: GrantFiled: May 16, 2012Date of Patent: March 24, 2015Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Margaret Clagett-Dame, Lori A. Plum, Grazia Chiellini
-
Publication number: 20150079206Abstract: This invention relates to the use of trigonelline compounds to increase muscle weight during periods of activity or to inhibit muscle loss during periods of inactivity.Type: ApplicationFiled: November 20, 2014Publication date: March 19, 2015Inventors: Angelika FRIEDEL, Karin KURATLI, Christof WEHRLI, Karin WERTZ, Swen WOLFRAM, Ying WANG-SCHMIDT
-
Publication number: 20150079164Abstract: The present disclosure relates to food supplement, dietary supplement, nutritional supplement, over-the-counter (OTC) supplement, medical food, or pharmaceutical grade supplement compositions comprising omega-3 fatty acids and vitamin D for use in improving at least one parameter associated with acne and/or eczema (dermatitis).Type: ApplicationFiled: March 15, 2013Publication date: March 19, 2015Applicant: Pronova Biopharma Norge ASInventors: David A. Fraser, Alexis Garras
-
Publication number: 20150072019Abstract: The present invention relates generally to 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl)-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of X-linked hypophosphatemic rickets (XLH), autosomal dominant hypophosphatemia rickets (ADHR), autosomal recessive hypophosphatemic rickets (ARHR), tumor-induced osteomalacia, post-renal transplant hypophosphatemia, epidermal nevus syndrome, osteoglophonic dysplasia or McCune-Albright syndrome.Type: ApplicationFiled: March 29, 2013Publication date: March 12, 2015Inventors: Michaela Kneissel, Vito Gaugnano, Diana Graus Porta, Simon Wöhrle
-
Publication number: 20150071874Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms or sequelae of disease. Chronic and acute conditions may be due to viral infections such as HIV and AIDS, neoplastic diseases stroke, kidney disease, urinary incontinence, autoimmune disorders, Parkinson's disease, prostate hypertrophy, aging, or the treatment of such diseases. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools against acute and chronic conditions in mammalian subjects.Type: ApplicationFiled: September 12, 2013Publication date: March 12, 2015Applicant: Biosuccess Biotech Co. Ltd.Inventors: Zheng Tao Han, Hung-Fong Chen
-
Publication number: 20150056276Abstract: The present disclosure relates to pharmaceutical compositions comprising omega-3 fatty acids and vitamin D for use in at least one of preventing and treating psoriasis, and to food supplement, dietary supplement, nutritional supplement, over-the-counter (OTC) supplement, medical food, or pharmaceutical grade supplement compositions comprising omega-3 fatty acids and vitamin D for use in improving at least one parameter associated with psoriasis.Type: ApplicationFiled: March 15, 2013Publication date: February 26, 2015Applicant: Pronova Biopharma Norge ASInventors: David A. Fraser, Alexis Garras